WO1999033792A3 - Prodrugs os aspartyl protease inhibitors - Google Patents
Prodrugs os aspartyl protease inhibitors Download PDFInfo
- Publication number
- WO1999033792A3 WO1999033792A3 PCT/US1998/027403 US9827403W WO9933792A3 WO 1999033792 A3 WO1999033792 A3 WO 1999033792A3 US 9827403 W US9827403 W US 9827403W WO 9933792 A3 WO9933792 A3 WO 9933792A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prodrugs
- relates
- protease inhibitors
- aspartyl protease
- pharmaceutical compositions
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 6
- 229940002612 prodrug Drugs 0.000 title abstract 6
- 239000003696 aspartic proteinase inhibitor Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20102/99A AU2010299A (en) | 1997-12-24 | 1998-12-23 | Prodrugs os aspartyl protease inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6880697P | 1997-12-24 | 1997-12-24 | |
US60/068,806 | 1997-12-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999033792A2 WO1999033792A2 (en) | 1999-07-08 |
WO1999033792A3 true WO1999033792A3 (en) | 1999-09-16 |
Family
ID=22084811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/027403 WO1999033792A2 (en) | 1997-12-24 | 1998-12-23 | Prodrugs os aspartyl protease inhibitors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2010299A (en) |
WO (1) | WO1999033792A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE42889E1 (en) | 1992-08-25 | 2011-11-01 | G.D. Searle Llc | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US8143421B2 (en) | 2002-03-12 | 2012-03-27 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors |
USRE43596E1 (en) | 1992-08-25 | 2012-08-21 | G.D. Searle Llc | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
US6617310B2 (en) * | 2000-07-19 | 2003-09-09 | Bristol-Myers Squibb Pharma Company | Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines |
EE05385B1 (en) | 2001-02-14 | 2011-02-15 | Tibotec�Pharmaceuticals�Ltd. | Broad-spectrum Á2- (Substituted Áamino) Benzothiazole Sulphonamides ÁkuiÁHIVÁProtease Inhibitors, Methods of Preparation, and UseUnited Pharmaceutical Formulations |
CN100491360C (en) | 2001-04-09 | 2009-05-27 | 泰博特克药品有限公司 | Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors |
AU2002310818B2 (en) | 2001-05-11 | 2007-12-13 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors |
BR0215260A (en) | 2001-12-21 | 2004-12-07 | Tibotec Pharm Ltd | Broad spectrum heterocyclically substituted phenyl sulfonamide HIV protease inhibitors |
IL165043A0 (en) | 2002-05-17 | 2005-12-18 | Tibotec Pharm Ltd | broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors |
CA2493940C (en) | 2002-08-14 | 2011-11-22 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors |
US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
US8193227B2 (en) | 2003-12-11 | 2012-06-05 | Abbott Laboratories | HIV protease inhibiting compounds |
UA83881C2 (en) | 2003-12-18 | 2008-08-26 | Янссен Фармацевтика Н.В. | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
EP1789029A2 (en) | 2004-08-30 | 2007-05-30 | Interstitial Therapeutics | Methods and compositions for the treatment of cell proliferation |
BRPI0516915A (en) | 2004-12-01 | 2008-03-11 | Devgen Nv | 5-carboxamido substituted thiazole derivatives which interact with ion channels, particularly with ion channels of the kv family |
NI200700147A (en) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP |
EP1938691A3 (en) | 2004-12-17 | 2009-07-22 | Devgen NV | Nematicidal compositions |
US20080194554A1 (en) * | 2005-03-11 | 2008-08-14 | Mclean Ed W | Hiv Protease Inhibitors |
AR053845A1 (en) | 2005-04-15 | 2007-05-23 | Tibotec Pharm Ltd | 5-TIAZOLILMETIL [(1S, 2R) -3 - [[(2-AMINO-6-BENZOXAZOLIL) SULFONIL)] (2-METHYLPROPIL) AMINO] -2-HYDROXY-1- (PHENYLMETIL) PROPIL] CARBAMATE AS A PHARMACY IMPROVER METABOLIZED BY THE CYCROCHROME P450 |
US8003627B2 (en) | 2005-10-21 | 2011-08-23 | Universiteit Antwerpen | Urokinase inhibitors |
AR057182A1 (en) | 2005-11-28 | 2007-11-21 | Tibotec Pharm Ltd | AMINOPHENYL SULFONAMIDE COMPOUNDS REPLACED AS HIV PROTEASE INHIBITORS |
AR058238A1 (en) | 2005-11-28 | 2008-01-23 | Tibotec Pharm Ltd | COMPOUNDS AND DERIVATIVES OF AMINOPHENYL SULFONAMIDE REPLACED AS HIV PROTEASE INHIBITORS |
EP3696171A1 (en) | 2006-07-07 | 2020-08-19 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
MX2009000456A (en) | 2006-07-13 | 2009-01-27 | Janssen Pharmaceutica Nv | Mtki quinazoline derivatives. |
WO2008028688A2 (en) | 2006-09-08 | 2008-03-13 | Bayer Schering Pharma Aktiengesellschaft | Compounds and methods for 18f labeled agents |
ES2603617T3 (en) | 2007-02-23 | 2017-02-28 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP2185562B1 (en) | 2007-07-27 | 2015-12-02 | Janssen Pharmaceutica, N.V. | Pyrrolopyrimidines useful for the treatment of proliferative diseases |
EP2053033A1 (en) | 2007-10-26 | 2009-04-29 | Bayer Schering Pharma AG | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
EP2283024B1 (en) | 2008-03-10 | 2013-05-15 | Janssen Pharmaceutica, N.V. | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
EP2116236A1 (en) | 2008-04-21 | 2009-11-11 | Université de Mons-Hainaut | Bisbenzamidine derivatives for use as antioxidant |
WO2011061295A1 (en) | 2009-11-19 | 2011-05-26 | Blue Medical Devices Bv | Narrow profile composition-releasing expandable medical balloon catheter |
WO2011141515A1 (en) | 2010-05-14 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Diagnostic agents for amyloid beta imaging |
US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
EP2700396A3 (en) | 2012-06-20 | 2015-04-29 | Sylphar Nv | Strip for the delivery of oral care compositions |
US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
WO2016083490A1 (en) | 2014-11-27 | 2016-06-02 | Remynd Nv | Compounds for the treatment of amyloid-associated diseases |
KR20180006389A (en) | 2015-04-28 | 2018-01-17 | 뉴사우쓰 이노베이션스 피티와이 리미티드 | NAD + targeting for the treatment of chemotherapy and radiotherapy induced cognitive impairment, neuropathy and inactivity |
PL3621963T3 (en) | 2017-05-11 | 2024-05-20 | Remynd N.V. | Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders |
BR112022016733A2 (en) | 2020-02-24 | 2022-10-11 | Univ Leuven Kath | PYRROLPIRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS |
JP2024500543A (en) | 2020-12-22 | 2024-01-09 | ルクセンブルク インスティテュート オブ ヘルス(エルアイエイチ) | Conolidine analogs as selective ACKR3 modulators for the treatment of cancer and cardiovascular diseases |
US20240002351A1 (en) | 2021-03-04 | 2024-01-04 | Universiteit Antwerpen | Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer |
CN117500772A (en) | 2021-05-31 | 2024-02-02 | 泰利克斯制药(创新)私人有限公司 | Improved prostate specific membrane antigen targeted radiopharmaceuticals and uses thereof |
EP4387629A1 (en) | 2021-08-18 | 2024-06-26 | Katholieke Universiteit Leuven KU Leuven Research & Development | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues |
WO2023046900A1 (en) | 2021-09-23 | 2023-03-30 | Katholieke Universiteit Leuven | Ribonucleoside analogues against -sars-cov-2 |
WO2023241799A1 (en) | 2022-06-15 | 2023-12-21 | Université Libre de Bruxelles | Flavanols for use in the treatment of retroviral infections |
WO2024062043A1 (en) | 2022-09-21 | 2024-03-28 | Universiteit Antwerpen | Substituted phenothiazines as ferroptosis inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005639A1 (en) * | 1992-09-08 | 1994-03-17 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of hiv-aspartyl protease |
WO1995006030A1 (en) * | 1993-08-24 | 1995-03-02 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
WO1995024385A1 (en) * | 1994-03-07 | 1995-09-14 | Vertex Pharmaceuticals Incorporated | Sulphonamide derivatives as aspartyl protease inhibitors |
WO1996033184A1 (en) * | 1995-04-19 | 1996-10-24 | Vertex Pharmaceuticals Incorporated | Thf-containing sulfonamide inhibitors of aspartyl protease |
-
1998
- 1998-12-23 AU AU20102/99A patent/AU2010299A/en not_active Abandoned
- 1998-12-23 WO PCT/US1998/027403 patent/WO1999033792A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005639A1 (en) * | 1992-09-08 | 1994-03-17 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of hiv-aspartyl protease |
US5585397A (en) * | 1992-09-08 | 1996-12-17 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
WO1995006030A1 (en) * | 1993-08-24 | 1995-03-02 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
WO1995024385A1 (en) * | 1994-03-07 | 1995-09-14 | Vertex Pharmaceuticals Incorporated | Sulphonamide derivatives as aspartyl protease inhibitors |
WO1996033184A1 (en) * | 1995-04-19 | 1996-10-24 | Vertex Pharmaceuticals Incorporated | Thf-containing sulfonamide inhibitors of aspartyl protease |
Non-Patent Citations (2)
Title |
---|
J.M. BALKOVEC ET AL, J. MED. CHEM., vol. 35, no. 1, 1992, pages 194 - 198, XP002104270 * |
S. SAWADA ET AL, CURR. PHARM. DES., vol. 1, no. 1, 1995, pages 113 - 132, XP002104269 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE42889E1 (en) | 1992-08-25 | 2011-11-01 | G.D. Searle Llc | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
USRE43596E1 (en) | 1992-08-25 | 2012-08-21 | G.D. Searle Llc | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US8143421B2 (en) | 2002-03-12 | 2012-03-27 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted benzimidazole sulfonamide HIV protease inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO1999033792A2 (en) | 1999-07-08 |
AU2010299A (en) | 1999-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999033792A3 (en) | Prodrugs os aspartyl protease inhibitors | |
WO1999033793A3 (en) | Prodrugs of aspartyl protease inhibitors | |
CA2231700A1 (en) | Prodrugs of aspartyl protease inhibitors | |
RS77904A (en) | Oral administration form for difficulty soluble basic active ingredients which are applied orally | |
HUP0104718A2 (en) | Micronized eplerenone compositions and process for their preparation | |
CA2217737A1 (en) | Thf-containing sulfonamide inhibitors of aspartyl protease | |
HUP0302131A2 (en) | Pharmaceutical tramadol salts, pharmaceutical compositions containing them | |
NO20024177D0 (en) | Pharmaceutical preparations containing azetidine derivatives, the novel derivatives and their preparation | |
NO20043101L (en) | Pharmaceutical mixtures of orally active taxane derivatives that have enhanced bioavailability | |
HRP20020428B1 (en) | Bicyclic amino acids as pharmaceutical agents | |
MY137777A (en) | Inhibitors of aspartyl protease | |
HUP0202745A2 (en) | Preventive and therapeutic agents for treatment of eye diseases | |
AU3485800A (en) | Inhibitors of aspartyl protease | |
HUP0300863A2 (en) | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide, process for producing it and pharmaceutical composition containing it | |
WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
EP1411956B8 (en) | Use of oversulfated polysaccharides as inhibitors of hiv | |
HK1041000A1 (en) | Novel pyrimidine derivatives and processes for thepreparation thereof. | |
CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
ZA200207586B (en) | Diphenyl ketoaldehyde derivatives with anti-HIV activity. | |
AU2002220654A1 (en) | Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders | |
BR0014351A (en) | Formulation and process of vasopressin antagonist | |
WO2003105826A3 (en) | "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors." | |
MX9708057A (en) | Thf-containing sulfonamide inhibitors of aspartyl protease. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |